Hydroxychloroquine has been tested in over 50 cancer clinical trials since 2010. The results are simultaneously the most exciting and most confusing in drug repurposing: 85% response rates in one cancer, 0% in another, tumors that shrink without patients living longer, and an immune paradox that no researcher has resolved.
This is not a generic overview. This is every significant data point from 15 years of HCQ oncology research, including three newly discovered mechanisms (2024–2025), the trials that succeeded, the trials that failed catastrophically, and the structural reasons nobody can get a Phase III funded.
Three New Anti-Cancer Mechanisms Discovered (2024–2025)
For 15 years, the narrative was simple: HCQ blocks autophagy, cancer cells die. That narrative is now collapsing. Three discoveries have fundamentally complicated the picture:
Mechanism 1: MHC-I Restoration (AACR, April 2025)
Cancer cells evade immune detection by degrading MHC-I molecules (their “identity tags”) through autophagy. HCQ reverses this process.
The data: HCQ significantly elevated membrane MHC-I protein on melanoma (A-375), lung cancer (NCI-H2122), ovarian cancer (OVCAR-8), and glioblastoma (U-87 MG) cells (p < 0.01). The elevation sustained 72 hours after HCQ removal. Pre-treatment with HCQ significantly enhanced T-cell killing of NY-ESO-1 positive tumors.
Why this matters: This reframes HCQ as a potential immunotherapy enhancer — it makes tumors visible to the immune system again. But this directly contradicts another finding (see “The Immune Paradox” below).
Mechanism 2: Myeloperoxidase Inhibition (Journal of Inflammation, 2025)
HCQ directly binds myeloperoxidase (MPO) via interaction near the heme group (Kd = 9.74 mM), blocking enzymatic activity. MPO drives neutrophil-mediated metastasis. In metastatic pancreatic cancer patients receiving neoadjuvant chemotherapy, this anti-metastatic mechanism was validated.
This is entirely unrelated to autophagy. It suggests HCQ may prevent cancer spread through innate immune modulation rather than direct tumor cell killing.
Mechanism 3: PAR-4 Tumor Suppressor Induction
In Phase I clinical trials, tumor cell apoptosis (death) was detected ONLY in patients whose plasma PAR-4 protein levels rose. Patients without PAR-4 elevation showed no tumor response — regardless of autophagy marker changes.
The implication is radical: The actual anti-cancer mechanism of HCQ may have nothing to do with autophagy. If confirmed, 15 years of trial design based on “autophagy inhibition” has been targeting the wrong pathway.
Cancer Cell Resistance: Also Not Autophagy (Cell Cycle, 2024)
Whole-genome screening at MUSC Hollings Cancer Center showed that cancer cells develop HCQ resistance through cell division, metabolic, and drug export pathways — NOT by restoring autophagy. Researcher Joe Delaney: “processes unrelated to autophagy may be the most important for cancer cells to survive this therapy.”
The Complete Trial Scoreboard
Melanoma: Where HCQ Actually Works
BAMM Trial (Clinical Cancer Research, 2022)
The single most impressive HCQ cancer trial to date:
- Design: Phase I/II, dabrafenib + trametinib + HCQ 1200mg/day
- Patients: 34 with BRAF V600-mutant melanoma
- Response rate: 85% (vs. 43% for similar patients in DREAMseq study)
- Complete response: 41%
- Median PFS: 11.2 months (1-year PFS: 48.2%)
- No dose-limiting toxicities. No ocular toxicity.
The 41% complete response rate — meaning no detectable cancer remaining — is extraordinary for a $20/month generic drug added to an existing regimen.
BAMM2/EA6191 (Recruiting, 2024–present)
The definitive randomized test. ECOG-ACRIN led. PI: Ravi Amaravadi, UPenn. Dabrafenib + trametinib + HCQ vs. placebo in Stage IIIC/IV BRAF V600E/K melanoma with elevated LDH after immunotherapy progression. Results expected 2027–2028.
LIMIT Trial (NCT04464759, Recruiting)
Testing HCQ + nivolumab and/or ipilimumab. Critical because preclinical data suggests HCQ may HARM checkpoint inhibitor therapy. This trial will resolve the paradox.
Breast Cancer: The Dormancy Revolution
CLEVER Trial (Nature Medicine, March 2025)
Possibly the most significant HCQ cancer finding ever published:
- Concept: Target dormant tumor cells (DTCs) lurking in bone marrow after surgery
- Patients: 53 randomized to HCQ alone, everolimus alone, or HCQ+everolimus
- 3-year recurrence-free survival:
- HCQ alone: 91.7%
- Everolimus alone: 92.9%
- HCQ + everolimus: 100%
- DTC clearance from bone marrow: HCQ 80%, everolimus 78%, combo 87%
- 77-month follow-up: Only 2/51 patients (6%) had any recurrence
- Safety: No grade 4/5 toxicities
This trial redefines how HCQ might work in cancer: not killing active tumors, but eliminating the dormant cells that cause recurrence years later.
PALAVY Trial (NCT04841148, Recruiting)
Multi-institutional (Dana-Farber, UPenn, Fred Hutch, Georgetown, Vanderbilt, U of Chicago). Testing avelumab or HCQ +/- palbociclib to eliminate DTCs in early-stage ER+ breast cancer.
Phase I: HCQ + Palbociclib + Letrozole (npj Breast Cancer, 2025)
14 patients with ER+/HER2- metastatic breast cancer. RP2D: HCQ 800mg + palbociclib 75mg continuous + letrozole 2.5mg. Achieved tumor reductions of 11–30% with 79% having only Grade 1–2 toxicities. Notably used a lower continuous palbociclib dose (75mg vs standard 125mg).
Pancreatic Cancer: The Graveyard of HCQ Combinations
Every major MEK inhibitor + HCQ combination in pancreatic cancer has failed:
HOPE Trial — Binimetinib + HCQ (The Oncologist, February 2026)
- 34 patients, KRAS-mutant metastatic PDAC
- ORR: 6.5% (2 partial responses)
- Median PFS: 1.9 months; Median OS: 5.3 months
- Cardiac troponin elevation: 26%; QT prolongation: 21%
- Verdict: “Does not support continued development”
LY3214996 (ERK inhibitor) + HCQ (JCO Precision Oncology, 2025)
- 39 patients
- HCQ combination was WORSE than ERK inhibitor alone
- Median OS: 2.4 mo (combo) vs 4.6 mo (ERK alone)
Trametinib/HCQ German Cohort (2024)
- 19 patients, real-world use
- 0/13 evaluable patients responded
- Median OS: 68 days
The one pancreatic trial that worked — sort of:
Preoperative gemcitabine/nab-paclitaxel + HCQ 1200mg/day (NCT01978184):
- Pathologic response: 56% vs 10% (p = 0.00016)
- Near-complete response (Evans III): 20.6% vs 0%
- But median OS: 36 vs 32 months (p = 0.59, NOT significant)
This is the central paradox: dramatic tumor killing that doesn’t translate to longer life.
Other Cancers: Mixed Results
| Cancer | Combination | N | Key Result | Verdict |
|---|---|---|---|---|
| Renal cell carcinoma | Everolimus + HCQ | 38 | 67% DCR, PFS 6.3 mo (vs 4.0 historical) | Modestly positive |
| Colorectal | FOLFOX/Bev + HCQ | 19 | 52% response, 1-yr OS 74%; 2 MIs (1 fatal) | Positive efficacy, cardiac concern |
| Colorectal | Vorinostat/HCQ vs regorafenib | 42 | HCQ arm inferior (PFS 1.9 vs 4.35 mo) | Negative |
| NSCLC (KRAS) | Binimetinib + HCQ | 9 | 0% response, 89% progressive disease | Negative |
| Glioblastoma | RT + temozolomide + HCQ | — | Autophagy NOT inhibited at tolerable doses | Fundamentally limited |
| Prostate | HCQ monotherapy (PAR-4) | — | Presented ASCO 2025 | Data pending |
| Prostate | HCQ + itraconazole (HITMAN-PC) | — | Phase I enrolling 2025 | Ongoing |
| HCC | Sorafenib + HCQ | — | Preclinical: overcomes sorafenib resistance | Phase I ongoing |
| Multiple myeloma | Bortezomib + HCQ | — | HCQ did NOT enhance bortezomib effects | Negative |
Meta-Analysis: Pooled Data from 7 Trials (293 Patients)
- Overall response rate: RR 1.33 (p = 0.009)
- 6-month PFS: RR 1.72 (p < 0.001)
- 1-year OS: RR 1.39 (p < 0.001) — the only pooled survival benefit across all trials
- Best cancer type for HCQ: Glioblastoma (survival endpoints)
- Best combination: HCQ + gemcitabine (response rate)
The Three Paradoxes Nobody Has Resolved
Paradox 1: Shrinks Tumors, Doesn’t Save Lives
In metastatic pancreatic cancer: response rate improved from 21% to 38% (statistically significant), but 12-month overall survival was WORSE in the HCQ arm (41% vs 49%). This pattern — better response, same or worse survival — repeats across trial after trial.
Possible explanations:
- HCQ selects for resistant clones that are more aggressive on relapse
- Tumor shrinkage occurs through a different mechanism than durable disease control
- HCQ’s immunosuppressive effects cancel out its tumor-killing effects over time
Paradox 2: The Immune Double-Bind
| Finding | Source | Implication |
|---|---|---|
| HCQ upregulates MHC-I → tumors become visible to T-cells | AACR 2025 | Should HELP immunotherapy |
| HCQ suppresses CD8+ TILs, reverses anti-PD-1 benefit | PLOS ONE 2021 | Should HURT immunotherapy |
HCQ restores the “flag” on cancer cells but simultaneously disables the “soldiers” that need to see the flag. Net effect: unknown. The LIMIT trial (HCQ + nivolumab/ipilimumab) will provide the answer.
Paradox 3: Prevention Works, Treatment Doesn’t
- Lupus patients on 400mg/day HCQ for years: 30% lower cancer incidence (RR 0.70, meta-analysis)
- Cancer patients on 1200mg/day HCQ for months: No survival improvement in most trials
Hypotheses:
- Cancer prevention and treatment are fundamentally different biological challenges
- Chronic low-dose creates different pharmacological effects than acute high-dose
- PAR-4 induction (the actual mechanism?) requires sustained low exposure, not burst dosing
- The epidemiological finding may be confounded by lupus biology or surveillance bias
The Dose-Toxicity Trilemma
The fundamental problem with HCQ in oncology:
Autoimmune dose (400mg/day) → Insufficient tumor autophagy inhibition
Oncology dose (1200mg/day) → Still inconsistent autophagy inhibition in some tumors
Higher doses → Cardiac QT prolongation + irreversible retinal damageAt 600mg/day in glioblastoma, autophagy was NOT consistently inhibited. The BAMM melanoma trial used 1200mg/day and succeeded — but melanoma may be uniquely sensitive to HCQ’s non-autophagy mechanisms.
Retinal Damage at Oncology Doses
- 2/7 patients (29%) developed subclinical retinal toxicity at 1000mg/day within 11–17 months
- Standard ophthalmologic screening MISSED it
- Only high-resolution OCT and multifocal electroretinography detected the damage
- Damage is irreversible and may progress after stopping HCQ
- Concurrent tamoxifen (used in breast cancer) accelerates toxicity
- Concurrent docetaxel/cyclophosphamide (common chemo) may also accelerate toxicity
Cardiac Risk (HOPE Trial Data, 2026)
At 1200mg/day with binimetinib:
- Troponin T elevation: 26%
- QT prolongation: 21%
- Ejection fraction decrease: 9%
- Grade 3 QT prolongation was a dose-limiting toxicity
Why No Phase III Trial Exists After 15 Years
Three structural barriers prevent the definitive answer:
1. No Financial Incentive
HCQ is generic, costing $0.20/tablet. A Phase III oncology trial costs $50–150 million. No pharmaceutical company will invest this for a drug they cannot patent. Only government grants and academic groups can fund this — and they have limited budgets.
2. COVID Stigma
The politicization of HCQ during COVID-19 created a reputational hazard that extends to legitimate cancer research. Brookings Institute documented the narrative as: “It doesn’t work; it’s dangerous; if you believe in it there’s something wrong with you.” Researchers report difficulty discussing HCQ publicly without being associated with misinformation.
3. Mixed Results Don’t Attract Funding
Funding agencies want clear preliminary data. HCQ’s pattern of “improved response but not survival” is neither clearly positive nor clearly negative — it occupies a frustrating middle ground that makes it hard to justify $100M+ trials.
Next-Generation: What Replaces HCQ
The field is shifting toward purpose-built autophagy inhibitors:
DCC-3116 (Inlexisertib) — Deciphera Pharmaceuticals
- First-in-class ULK1/2 kinase inhibitor
- Blocks autophagy INITIATION (upstream) vs HCQ which blocks DEGRADATION (downstream)
- Phase 1/2 ongoing in KRAS/NRAS/BRAF-mutant cancers
- Being combined with sotorasib, trametinib, ripretinib
- Preclinical: tumor regression in NSCLC xenografts with sotorasib
GNS561 (Ezurpimtrostat)
- PPT1 inhibitor; Phase 1b completed in liver cancers
- RP2D: 200mg twice daily
- 25% disease stabilization; entering Phase 2 with atezolizumab-bevacizumab
DC661/DQ661 (Amaravadi Lab, UPenn)
- Critical advantage: maintains activity in acidic media — HCQ does NOT
- Tumors are acidic environments, which neutralizes HCQ before it reaches lysosomes
- Targets palmitoyl-protein thioesterase 1 (PPT1)
- Preclinical efficacy in melanoma, pancreatic, colorectal models
Lys05 — ~10x more cytotoxic than HCQ; water-soluble
Silylated HCQ Derivatives (2025 preprint) — Enhanced PARP-1 cleavage and autophagy blockade in breast and pancreatic cancer cells vs parent HCQ
Key Researchers and Active Trials (2026)
Principal Investigators
Ravi Amaravadi, MD (University of Pennsylvania)
- Leading global figure in autophagy inhibition for cancer
- PI on BAMM, BAMM2/EA6191, LIMIT melanoma trials
- Co-discovered PPT1 as molecular target; developed DC661/DQ661
- Founded Pinpoint Therapeutics to advance next-gen agents
Joe Delaney, PhD (MUSC Hollings Cancer Center)
- Identified non-autophagy resistance mechanisms
- Shifting the field’s understanding of how cancer escapes HCQ
Active Trials Worth Tracking
| NCT | Cancer | Combination | Phase | Status |
|---|---|---|---|---|
| EA6191 (BAMM2) | Melanoma (BRAF+, high LDH) | Dab + Tram + HCQ vs placebo | II | Recruiting |
| NCT04464759 (LIMIT) | Melanoma | Nivo +/- Ipi + HCQ | I/II | Recruiting |
| NCT04841148 (PALAVY) | Breast (dormancy) | Avelumab or HCQ +/- Palbociclib | II | Recruiting |
| NCT04523857 | Breast (MRD) | Abemaciclib +/- HCQ | II | Recruiting |
| NCT04316169 | Breast/solid tumors | HCQ + Abemaciclib + endocrine | I/II | Active |
| NCT04214418 | GI (KRAS) | Cobimetinib + Atezo + HCQ | I/II | Active |
| NCT04011410 | Prostate (oligomet) | HCQ monotherapy (PAR-4) | II | Active |
| NCT03037437 | HCC | Sorafenib + HCQ | I/II | Active |
| NCT05221320 | GI (RAS+) | Ulixertinib + HCQ | — | Recruiting |
India Context: The $5/Day Cancer Drug
Why India Matters
- India manufactures 70%+ of global HCQ supply (Ipca Laboratories, Zydus Cadila)
- Monthly cancer-dose cost in India: ₹1,080–2,700 ($13–33)
- Monthly cancer-dose cost in US: $45–120 (with coupons)
- No supply constraints, no prescription barriers to access
The Equity Argument
The ReDO project (Repurposing Drugs in Oncology) specifically identifies HCQ as relevant for developing countries where $15,000/month immunotherapy is inaccessible. A drug that costs ₹5/day and shows 85% response rates in melanoma — even with caveats — deserves different cost-benefit analysis in India vs the US.
Current Indian Landscape
- No Indian oncology guidelines include HCQ
- No India-specific clinical trials have been conducted
- Off-label prescribing is at physician discretion (less regulated than US)
- Major potential for physician-researcher led studies given drug accessibility
- Patient communities (CancerTreatmentsResearch.com) discuss Indian access
What the Evidence Actually Supports (Honest Assessment)
Strong evidence FOR:
- HCQ + dabrafenib + trametinib in BRAF-mutant melanoma (Phase I/II, 85% RR)
- HCQ + everolimus for breast cancer dormancy/recurrence prevention (100% RFS at 3 years)
- HCQ as a cancer preventive agent (epidemiological, 30% risk reduction)
Moderate evidence FOR:
- Neoadjuvant HCQ + gemcitabine/nab-paclitaxel in borderline-resectable pancreatic cancer (pathologic response, not survival)
- Everolimus + HCQ in renal cell carcinoma (modestly improved PFS)
Strong evidence AGAINST:
- Any MEK inhibitor + HCQ in pancreatic cancer (multiple failures)
- HCQ in KRAS-mutant NSCLC (0% response)
- HCQ with anti-PD-1 immunotherapy (preclinical harm signal)
- HCQ as monotherapy in any advanced cancer
Unknown (awaiting trial results):
- HCQ + immunotherapy combinations (LIMIT trial)
- Randomized HCQ benefit in melanoma (BAMM2 trial)
- Long-term recurrence prevention in breast cancer (PALAVY trial)
- PAR-4 mechanism in prostate cancer
Conclusion: A Drug Waiting for Better Science
HCQ in oncology is not a story of a wonder drug being suppressed. It’s a story of a blunt instrument being used where a scalpel is needed. The drug has real anti-cancer mechanisms — likely multiple — but at clinically achievable doses, it cannot reliably exploit them across all cancer types.
The next chapter will be written by:
- BAMM2 results (~2027): Does HCQ definitively help in melanoma?
- LIMIT results (~2028): Can HCQ safely combine with immunotherapy?
- DCC-3116 development: Can a purpose-built inhibitor succeed where HCQ fails?
- PAR-4 biology: Is autophagy inhibition even the right target?
For now, HCQ remains the most-studied, least-resolved repurposed drug in oncology — and at ₹5/day in India, one of the most accessible if the science eventually catches up.
Medical Disclaimer: This article reviews published clinical trial data for informational purposes. Hydroxychloroquine is NOT approved for cancer treatment. Do not self-medicate. All cancer treatment decisions should be made with your oncologist based on your specific diagnosis, staging, and molecular profile. Clinical trial enrollment remains the recommended route for accessing investigational HCQ-based cancer protocols.
Sources & References
- AACR Cancer Research 2025, Abstract 5827 — HCQ increases MHC-I on tumor cells
- Nature Medicine 2025 — CLEVER trial: HCQ + everolimus in breast cancer dormancy
- The Oncologist 2026 — Binimetinib + HCQ Phase I HOPE trial in pancreatic cancer
- Clinical Cancer Research 2022 — BAMM trial: dabrafenib + trametinib + HCQ in melanoma
- Journal of Inflammation 2025 — HCQ inhibits myeloperoxidase in metastatic PDAC
- Cell Cycle 2024 — Cancer cell resistance mechanisms to HCQ
- Annals of Medicine 2021 — Meta-analysis: antimalarial use and cancer risk reduction
- PMC 2021 — Phase II preoperative HCQ + gemcitabine/nab-paclitaxel in pancreatic cancer
- JAMA Oncology 2019 — Metastatic pancreatic cancer HCQ trial
- JCO Precision Oncology 2025 — LY3214996 + HCQ in pancreatic cancer
- Clinical Cancer Research 2019 — Everolimus + HCQ in renal cell carcinoma
- npj Breast Cancer 2025 — HCQ + palbociclib + letrozole Phase I
- PLOS ONE 2021 — HCQ impairs anti-PD-1 immunotherapy in melanoma
- PMC 2018 — Meta-analysis of autophagy inhibition in cancer trials (7 trials, 293 patients)
- PMC 2018 — PAR-4 tumor suppressor and HCQ clinical correlation
- PMC 2021 — Long-term neoadjuvant HCQ + gemcitabine survival data
- ECOG-ACRIN — BAMM2/EA6191 randomized melanoma trial
- ClinicalTrials.gov — LIMIT trial, HCQ + nivolumab/ipilimumab (NCT04464759)
- ClinicalTrials.gov — PALAVY trial, breast cancer dormancy (NCT04841148)
- JCO 2025 — PAR-4 prostate cancer trial presented at ASCO
- Cancer Research Communications 2025 — HITMAN-PC Phase I (HCQ + itraconazole)
- Deciphera Pharmaceuticals — DCC-3116 (inlexisertib) pipeline
- Cancer Discovery 2019 — PPT1 as molecular target of chloroquine derivatives
- PMC 2024 — Comprehensive autophagy inhibitors review
- PMC 2024 — AIO Trametinib/HCQ retrospective cohort, Germany
- PMC Binimetinib + HCQ in KRAS-mutant NSCLC Phase II
- British Journal of Cancer 2022 — Vorinostat/HCQ vs regorafenib in colorectal cancer
- ReDO Project — Chloroquine/HCQ as anti-cancer agents
- University of Arizona Cancer Center 2024 — HCQ + lapatinib for breast cancer brain metastases
- AAO 2026 — Revised recommendations for HCQ retinal screening
- 1mg.com — HCQS 200 tablet pricing, India
- GoodRx — US hydroxychloroquine pricing, 2026
- UPenn Amaravadi Lab — Publications and research
- Brookings Institute — Understanding medical uncertainty in the hydroxychloroquine debate